DE69331368T2 - Herstellung und Benützung eines Metastasehemmendes Proteines. - Google Patents
Herstellung und Benützung eines Metastasehemmendes Proteines.Info
- Publication number
- DE69331368T2 DE69331368T2 DE69331368T DE69331368T DE69331368T2 DE 69331368 T2 DE69331368 T2 DE 69331368T2 DE 69331368 T DE69331368 T DE 69331368T DE 69331368 T DE69331368 T DE 69331368T DE 69331368 T2 DE69331368 T2 DE 69331368T2
- Authority
- DE
- Germany
- Prior art keywords
- protein
- amino acid
- cell
- acid sequence
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 82
- 102000004169 proteins and genes Human genes 0.000 title claims description 81
- 206010027476 Metastases Diseases 0.000 title claims description 41
- 230000009401 metastasis Effects 0.000 title claims description 35
- 230000002401 inhibitory effect Effects 0.000 title claims description 27
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 210000004027 cell Anatomy 0.000 claims description 46
- 239000000126 substance Substances 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 201000011510 cancer Diseases 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000008363 phosphate buffer Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims description 7
- 239000000032 diagnostic agent Substances 0.000 claims description 7
- 229940039227 diagnostic agent Drugs 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 235000015097 nutrients Nutrition 0.000 claims description 7
- 208000000389 T-cell leukemia Diseases 0.000 claims description 6
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- JXGJJQJHXHXJQF-CIUDSAMLSA-N Asp-Met-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O JXGJJQJHXHXJQF-CIUDSAMLSA-N 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 23
- 150000001413 amino acids Chemical group 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001622557 Hesperia Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/72—Undefined extracts from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP28113692A JP3439490B2 (ja) | 1992-09-28 | 1992-09-28 | 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69331368D1 DE69331368D1 (de) | 2002-01-31 |
| DE69331368T2 true DE69331368T2 (de) | 2002-08-08 |
Family
ID=17634871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69331368T Expired - Fee Related DE69331368T2 (de) | 1992-09-28 | 1993-09-28 | Herstellung und Benützung eines Metastasehemmendes Proteines. |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US5498697A (OSRAM) |
| EP (1) | EP0594311B1 (OSRAM) |
| JP (1) | JP3439490B2 (OSRAM) |
| KR (1) | KR100294977B1 (OSRAM) |
| DE (1) | DE69331368T2 (OSRAM) |
| TW (1) | TW241268B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2287872C (en) | 1997-05-12 | 2010-07-27 | Aphton Corporation | Immunogenic compositions to the cck-b/gastrin receptor and methods for the treatment of tumors |
| US20040001842A1 (en) * | 1997-05-12 | 2004-01-01 | Dov Michaeli | Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors |
| US6387661B1 (en) * | 2001-03-23 | 2002-05-14 | Pe Corporation (Ny) | Nucleic acid molecules encoding human aminoacylase proteins |
| JP2005508838A (ja) | 2001-03-23 | 2005-04-07 | アフトン コーポレーション | 膵癌の組合せ治療 |
| US20090191232A1 (en) | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| AU2002326356A1 (en) * | 2001-07-09 | 2003-01-29 | Aphton Corporation | Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| WO2004088326A2 (en) * | 2003-03-28 | 2004-10-14 | Aphton Corporation | Gastrin hormone immunoassays |
| EP1794586B1 (en) | 2004-09-22 | 2013-01-30 | Cancer Advances, Inc., | Monoclonal antibodies to progastrin |
| KR102772810B1 (ko) | 2017-06-15 | 2025-02-28 | 캔서 어드밴시스 아이엔씨 | 종양 및 암에 대한 체액성 및 세포 면역을 유도하기 위한 조성물 및 방법 |
| US12150978B2 (en) | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
| CN111704658B (zh) * | 2018-06-11 | 2021-11-16 | 北京市农林科学院 | 具有消脂护肝功能的毛木耳糖肽及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925332A (ja) * | 1982-08-04 | 1984-02-09 | Mochida Pharmaceut Co Ltd | 抗腫瘍性糖蛋白質の製法 |
| JPS60112718A (ja) * | 1983-11-21 | 1985-06-19 | Kyorin Pharmaceut Co Ltd | 抗腫瘍作用を示す蛋白性物質及びその製造方法 |
| JP2926409B2 (ja) * | 1989-05-22 | 1999-07-28 | 株式会社林原生物化学研究所 | 癌転移抑制因子の製造方法 |
-
1992
- 1992-09-28 JP JP28113692A patent/JP3439490B2/ja not_active Expired - Fee Related
-
1993
- 1993-09-25 TW TW082107913A patent/TW241268B/zh not_active IP Right Cessation
- 1993-09-27 KR KR1019930019832A patent/KR100294977B1/ko not_active Expired - Fee Related
- 1993-09-27 US US08/127,278 patent/US5498697A/en not_active Expired - Fee Related
- 1993-09-28 EP EP93307668A patent/EP0594311B1/en not_active Expired - Lifetime
- 1993-09-28 DE DE69331368T patent/DE69331368T2/de not_active Expired - Fee Related
-
1995
- 1995-11-13 US US08/555,860 patent/US5585474A/en not_active Expired - Fee Related
-
1997
- 1997-04-09 US US08/827,864 patent/US5827691A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TW241268B (OSRAM) | 1995-02-21 |
| EP0594311A1 (en) | 1994-04-27 |
| US5498697A (en) | 1996-03-12 |
| KR940007056A (ko) | 1994-04-26 |
| JP3439490B2 (ja) | 2003-08-25 |
| JPH06107693A (ja) | 1994-04-19 |
| EP0594311B1 (en) | 2001-12-19 |
| US5585474A (en) | 1996-12-17 |
| US5827691A (en) | 1998-10-27 |
| DE69331368D1 (de) | 2002-01-31 |
| KR100294977B1 (ko) | 2001-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3852255T2 (de) | Tumor-Nekrosisfaktor-Inhibitor-Protein und dessen Reinigung. | |
| EP1003786B1 (de) | Peptid mit radioprotektiver wirkung | |
| DE69431473T2 (de) | Inhibitor der stammzellproliferation und seine verwendung | |
| DE69520088T2 (de) | Interferon-gamma-induzierendes Polypeptid monoklonal Antikörper, und Zusammensetzung für Interferon-gamma gebunden Krankheiten | |
| DE69006100T2 (de) | Fibronektin-Derivate. | |
| DE3750915T2 (de) | Für Antitumor-Polypeptide kodierende DNS, die Polypeptide und diese Polypeptide enthaltenden Antitumor-Wirkstoffe. | |
| DD159782A5 (de) | Verfahren zur herstellung eines eine immunologische oder biologische aktivitaet von humanleukozyten-interferon aufweisendes polypeptids | |
| DD251785A5 (de) | Verfahren zur Herstellung eines menschlichen, physiologisch aktiven Polypeptids mit Tnf-Aktivität | |
| DE68908633T2 (de) | Polypeptide mit zellenverstreuender Aktivität. | |
| DE19535853C2 (de) | Varianten des rekombinanten humanen Interferon-gamma, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DD219505A5 (de) | Verfahren zur herstellung von schweine-wachstumshormonaehnlichen polypeptiden | |
| DE68920931T2 (de) | Rekombinanter natürlicher Killerzellen-Aktivator. | |
| EP0291804A2 (de) | Proteine mit TNF-Wirkung | |
| DE4404124C2 (de) | TNF-Muteine, kodierendes Polynucleotid, Vektor, Mikroorganismus, Verfahren zur Herstellung der TNF-Muteine und TNF-Muteine enthaltende pharmazeutische Zusammensetzung | |
| AT400443B (de) | Menschliche mangan-superoxiddismutase cdna, ihre expression in bakterien und verfahren zur gewinnung enzymatisch aktiver, menschlicher mangan-superoxiddismutase | |
| DE69131421T2 (de) | Für den rezeptor des granulozytenkolonie stimulierenden faktors kodierende dns | |
| DE3855078T2 (de) | Verfahren zur herstellung von cystatin-c oder abwandlungen davon und dns-sequenz zur ausführung dieser methode | |
| DE69024693T2 (de) | Gene, die ein Protein mit menschlicher MACIF-Aktivität kodieren, Expressionsvektoren mit diesen Genen, Transformantenzellen und Proteine mit menschlicher MACIF-Aktivität | |
| DE112005000737T5 (de) | Mit Heparansulfat-Zuckerketten modifizierte Heparin-bindende Proteine, Verfahren zur Erzeugung derselben und Arzneimittel, welche dieselben enthalten | |
| US5498697A (en) | Protein possessing metastasis-inhibitory activity | |
| DE69022901T2 (de) | Streptokinase-Proteine, entsprechende Gene, entsprechende Plasmide und Verfahren zu deren Herstellung. | |
| DE68907941T2 (de) | Polypeptide mit Zellausdehnungs-Aktivität. | |
| DE68908138T2 (de) | Polypeptide mit Zellausdehnungs-Aktivität. | |
| EP0250000B1 (de) | Neue Polypeptide, ihre Herstellung und ihre Verwendung | |
| DE68923496T2 (de) | Verfahren zur Herstellung von motilinähnlichen Polypeptiden und seine Expression. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |